Close

Drug Research

Genomic Studies Utilize Scale As Clinical Utility Catches Up

An innovative system for monitoring chromosomal fragility and copy number alterations in particularly lethal tumours was described earlier this July by researchers from Cambridge University...

Novavax COVID-19 Vaccine Is Fourth US Option Now Available

As infections in the U.S. continue to be at high levels, the Food and Drug Administration on 13th July approved a fourth vaccination for...

Alice – a tireless hero in the fight against Covid-19

Aspen successfully expands CMO activities with filling equipment from Syntegon At first sight, anesthetics and vaccines don’t have much in common: while the first have...

New Drug Mix From ICR And The Royal Marsden Shows Promise

The findings of a phase 1 trial examining a medication mixture targeting multiple mutant variants of cancer's 'death star' protein have been released by...

Citius Pharma selects global CRO, Biorasi to help expand phase 3 Mino-Lok trial to additional sites outside US

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced that it has selected Biorasi, LLC (Biorasi), a global clinical research organization (CRO), to help expand...

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

Oragenics, Inc. announced it has entered into an agreement with KBI Biopharma, Inc. for the process transfer, process optimization and cGMP manufacturing of the...

WuXi ATU Announces Launch of TESSA Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSAâ„¢). This technology is a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read